| Dopamine | |
|---|---|
| File:Dopamin - Dopamine.svg | |
| File:Dopamine-3d-CPK.png | |
| IUPAC name | 4-(2-aminoethyl)benzene-1,2-diol |
| Other names | 2-(3,4-dihydroxyphenyl)ethylamine; 3,4-dihydroxyphenethylamine; 3-hydroxytyramine; DA; Intropin Revivan; Oxytyramine |
| Identifiers | |
| CAS number | [51-61-6] |
| PubChem | |
| SMILES | |
| Properties | |
| Molecular formula | C8H11NO2 |
| Molar mass | 153.178 |
| Melting point |
128 °C (401 K) |
| Solubility in water | 60.0 g/100 ml (? °C), solid |
| Hazards | |
| R/S statement | R: 36/37/38 S: 26-36 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox references | |
Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area.[1] Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary.
Dopamine can be supplied as a medication that acts on the sympathetic nervous system, producing effects such as increased heart rate and blood pressure. However, because dopamine cannot cross the blood-brain barrier, dopamine given as a drug does not directly affect the central nervous system. To increase the amount of dopamine in the brains of patients with diseases such as Parkinson's disease and dopa-responsive dystonia, L-DOPA (levodopa), which is the precursor of dopamine, can be given because it can cross the blood-brain barrier.
History[]
Dopamine was discovered in 1952 by Arvid Carlsson and Nils-Åke Hillarp at the Laboratory for Chemical Pharmacology of the National Heart Institute of Sweden. It was named dopamine because it was a monoamine, and its synthetic precursor was 3,4-dihydroxyphenylalanine (L-DOPA).[2] Arvid Carlsson was awarded the 2000 Nobel Prize in Physiology or Medicine for showing that dopamine is not just a precursor of norepinephrine (noradrenaline) and epinephrine (adrenaline) but a neurotransmitter, as well.
Dopamine was first synthesized artificially in 1910 by George Barger and James Ewens at Wellcome Laboratories in London, England.[3]
Biochemistry[]
Biosynthesis of Dopamine
Name and family[]
Dopamine has the chemical formula C6H3(OH)2-CH2-CH2-NH2. Its chemical name is "4-(2-aminoethyl)benzene-1,2-diol" and its abbreviation is "DA."
As a member of the catecholamine family, dopamine is a precursor to norepinephrine (noradrenaline) and then epinephrine (adrenaline) in the biosynthetic pathways for these neurotransmitters.
Biosynthesis[]
Dopamine is biosynthesized in the body (mainly by nervous tissue and the medulla of the adrenal glands) first by the hydroxylation of the amino acid L-tyrosine to L-DOPA via the enzyme tyrosine 3-monooxygenase, also known as tyrosine hydroxylase, and then by the decarboxylation of L-DOPA by aromatic L-amino acid decarboxylase (which is often referred to as dopa decarboxylase). In some neurons, dopamine is further processed into norepinephrine by dopamine beta-hydroxylase.
In neurons, dopamine is packaged after synthesis into vesicles, which are then released into the synapse in response to a presynaptic action potential.
Inactivation and degradation[]
Dopamine is inactivated by reuptake via the dopamine transporter, then enzymatic breakdown by catechol-O-methyl transferase (COMT) and monoamine oxidase (MAO). Dopamine that is not broken down by enzymes is repackaged into vesicles for reuse.
Dopamine may also simply diffuse away from the synapse, and help to regulate blood pressure.
Functions in the brain[]
Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.
The phasic responses of dopamine neurons are observed when an unexpected reward is presented. These responses transfer to the onset of a conditioned stimulus after repeated pairings with the reward. Further, dopamine neurons are depressed when the expected reward is omitted. Thus, dopamine neurons seem to encode the prediction error of rewarding outcomes. In nature, we learn to repeat behaviors that lead to maximize rewards. Dopamine is therefore believed to provide a teaching signal to parts of the brain responsible for acquiring new behavior. Temporal difference learning provides a computational model describing how the prediction error of dopamine neurons is used as a teaching signal.
In insects, a similar reward system exists, using octopamine, a chemical relative of dopamine.[4]
Anatomy[]
Dopaminergic neurons form a neurotransmitter system which originates in substantia nigra pars compacta, ventral tegmental area (VTA), and hypothalamus. These project axons to large areas of the brain through four major pathways:
- Mesocortical pathway
- Mesolimbic pathway
- Nigrostriatal pathway
- Tuberoinfundibular pathway
This innervation explains many of the effects of activating this dopamine system. For instance, the mesolimbic pathway connects the VTA and nucleus accumbens, both are central to the brain reward system.[5]
Movement[]
Via the dopamine receptors D1, D2, D3, D4 and D5, dopamine reduces the influence of the indirect pathway, and increases the actions of the direct pathway within the basal ganglia. Insufficient dopamine biosynthesis in the dopaminergic neurons can cause Parkinson's disease, in which a person loses the ability to execute smooth, controlled movements.
Cognition and frontal cortex[]
In the frontal lobes, dopamine controls the flow of information from other areas of the brain. Dopamine disorders in this region of the brain can cause a decline in neurocognitive functions, especially memory, attention, and problem-solving. Reduced dopamine concentrations in the prefrontal cortex are thought to contribute to attention deficit disorder. It has been found that D1 receptors are responsible for the cognitive-enhancing effects of dopamine.[6] On the converse, however, anti-psychotic medications act as dopamine antagonists and are used in the treatment of positive symptoms in schizophrenia.
Regulating prolactin secretion[]
Dopamine is the primary neuroendocrine inhibitor of the secretion of prolactin from the anterior pituitary gland. [7] Dopamine produced by neurons in the arcuate nucleus of the hypothalamus is secreted into the hypothalamo-hypophysial blood vessels of the median eminence, which supply the pituitary gland. The lactotrope cells that produce prolactin, in the absence of dopamine, secrete prolactin continuously; dopamine inhibits this secretion. Thus, in the context of regulating prolactin secretion, dopamine is occasionally called prolactin-inhibiting factor (PIF), prolactin-inhibiting hormone (PIH), or prolactostatin. Prolactin also seems to inhibit dopamine release, such as after orgasm, and is chiefly responsible for the refractory period.
Motivation and pleasure[]
Reinforcement[]
Dopamine is commonly associated with the pleasure system of the brain, providing feelings of enjoyment and reinforcement to motivate a person proactively to perform certain activities. Dopamine is released (particularly in areas such as the nucleus accumbens and ventral tegmental area) by naturally rewarding experiences such as food, sex,[8][9] drugs, and neutral stimuli that become associated with them. This theory is often discussed in terms of drugs such as cocaine, nicotine, and amphetamines, which seem to directly or indirectly lead to an increase of dopamine in these areas, and in relation to neurobiological theories of chemical addiction, arguing that these dopamine pathways are pathologically altered in addicted persons. Recent studies indicate that aggression may also stimulate the release of dopamine in this way.
Reuptake inhibition, expulsion[]
Cocaine and amphetamines inhibit the re-uptake of dopamine; however, they both influence separate mechanisms of action. Cocaine is a dopamine transporter blocker that competitively inhibits dopamine uptake to increase the lifetime of dopamine and augments an overabundance of dopamine (an increase of up to 150 percent) within the parameters of the dopamine neurotransmitters.
Like cocaine, amphetamines increase the concentration of dopamine in the synaptic gap, but by a different mechanism. Amphetamines are similar in structure to dopamine, and so can enter the terminal button of the presynaptic neuron via its dopamine transporters as well as by diffusing through the neural membrane directly. By entering the presynaptic neuron, amphetamines force dopamine molecules out of their storage vesicles and expel them into the synaptic gap by making the dopamine transporters work in reverse.
Incentive salience[]
Dopamine's role in experiencing pleasure has been questioned by several researchers. It has been argued that dopamine is more associated with anticipatory desire and motivation (commonly referred to as "wanting") as opposed to actual consummatory pleasure (commonly referred to as "liking"). Dopamine is not released when unpleasant or aversive stimuli are encountered, in effect enhancing the pleasure of avoidance or removal of the unpleasant stimuli.
Dopamine, learning, and reward-seeking behavior[]
Dopaminergic neurons of the midbrain are the main source of dopamine in the brain.[10] Dopamine has been shown to be involved in the control of movements, the signaling of error in prediction of reward, motivation, and cognition. Cerebral dopamine depletion is the hallmark of Parkinson's disease.[10] Other pathological states have also been associated with dopamine dysfunction, such as schizophrenia, autism, and attention deficit hyperactivity disorder in children, as well as drug abuse. Dopamine is closely associated with reward-seeking behaviors, such as approach, consumption, and addiction.[10] Recent researches suggest that the firing of dopaminergic neurons is a motivational substance as a consequence of reward-anticipation. This hypothesis is based on the evidence that, when a reward is greater than expected, the firing of certain dopaminergic neurons increases, which consequently increases desire or motivation towards the reward.[10]
Animal studies[]
Clues to dopamine's role in motivation, desire, and pleasure have come from studies performed on animals. In one such study, rats were depleted of dopamine by up to 99 percent in the nucleus accumbens and neostriatum using 6-hydroxydopamine.[10] With this large reduction in dopamine, the rats would no longer eat by their own volition. The researchers then force-fed the rats food and noted whether they had the proper facial expressions indicating whether they liked or disliked it. The researchers of this study concluded that the reduction in dopamine did not reduce the rat's consummatory pleasure, only the desire to actually eat. In another study, mutant hyperdopaminergic (increased dopamine) mice show higher "wanting" but not "liking" of sweet rewards.[11]
The effects of drugs that reduce dopamine levels in humans[]
In humans, however, drugs that reduce dopamine activity (neuroleptics, e.g. some antipsychotics) have been shown to reduce motivation, and to cause anhedonia a.k.a. the inability to experience pleasure.[12] Selective D2/D3 agonists pramipexole and ropinirole, used to treat Restless legs syndrome, have limited anti-anhedonic properties as measured by the Snaith-Hamilton Pleasure Scale.[13] (The Snaith-Hamilton-Pleasure-Scale (SHAPS), introduced in English in 1995, assesses self-reported anhedonia in psychiatric patients.)
Additionally, users of stimulants often have depleted dopamine levels after withdrawal from these addictive substances.
Opioid and cannabinoid transmission[]
Opioid and cannabinoid transmission instead of dopamine may modulate consummatory pleasure and food palatability (liking).[14] This could explain why animals' "liking" of food is independent of brain dopamine concentration. Other consummatory pleasures, however, may be more associated with dopamine. One study found that both anticipatory and consummatory measures of sexual behavior (male rats) were disrupted by DA receptor antagonists.[15] Libido can be increased by drugs that affect dopamine, but not by drugs that affect opioid peptides or other neurotransmitters.
Sociability[]
Sociability is also closely tied to dopamine neurotransmission. Low D2 receptor-binding is found in people with social anxiety. Traits common to negative schizophrenia (social withdrawal, apathy, anhedonia) are thought to be related to a hyperdopaminergic state in certain areas of the brain. In instances of bipolar disorder, manic subjects can become hypersocial, as well as hypersexual. This is also credited to an increase in dopamine, because mania can be reduced by dopamine-blocking anti-psychotics.
Processing of pain[]
Dopamine has been demonstrated to play a role in pain processing in multiple levels of the central nervous system including the spinal cord [16], periaqueductal gray (PAG)[17], thalamus [18], basal ganglia[19] [20] insular cortex [21][22] and cingulate cortex.[23] Accordingly, decreased levels of dopamine have been associated with painful symptoms that frequently occur in Parkinson's disease.[24] Abnormalities in dopaminergic neurotransmission have also been demonstrated in painful clinical conditions, including burning mouth syndrome,[25] fibromyalgia [26] [27] and restless legs syndrome.[28] In general, the analgesic capacity of dopamine occurs as a result of dopamine D2 receptor activation; however, exceptions to this exist in the PAG, in which dopamine D1 receptor activation attenuates pain presumabley via activation of neurons involved in descending inhibition.[29] In addition, D1 receptor activation in the insular cortex appears to attenuate subsequent pain-related behavior.
Salience[]
Dopamine may also have a role in the salience ('noticeableness') of perceived objects and events, with potentially important stimuli such as: 1) rewarding things or 2) dangerous or threatening things seeming more noticeable or important.[30] This hypothesis argues that dopamine assists decision-making by influencing the priority, or level of desire, of such stimuli to the person concerned.
Behavior disorders[]
Pharmacological blockade of brain dopamine receptors increases rather than decreases drug-taking behavior. Since blocking dopamine decreases desire, the increase in drug-taking behaviour may be seen as not a chemical desire but as a deeply psychological desire to just 'feel something'.
Deficits in dopamine levels are implicated in attention-deficit hyperactivity disorder (ADHD), and stimulant medications used to successfully treat the disorder increase dopamine neurotransmitter levels, leading to decreased symptoms.
Latent inhibition and creative drive[]
Dopamine in the mesolimbic pathway increases general arousal and goal directed behaviors and decreases latent inhibition; all three effects increase the creative drive of idea generation. This has led to a three-factor model of creativity involving the frontal lobes, the temporal lobes, and mesolimbic dopamine.[31]
Links to psychosis[]
Abnormally high dopamine action has also been strongly linked to psychosis and schizophrenia,[32] Dopamine neurons in the mesolimbic pathway are particularly associated with these conditions. Evidence comes partly from the discovery of a class of drugs called the phenothiazines (which block D2 dopamine receptors) that can reduce psychotic symptoms, and partly from the finding that drugs such as amphetamine and cocaine (which are known to greatly increase dopamine levels) can cause psychosis.[33] Because of this, most modern antipsychotic medications, for example, Risperidone, are designed to block dopamine function to varying degrees.
Therapeutic use[]
Levodopa is a dopamine precursor used in various forms to treat Parkinson's disease and dopa-responsive dystonia. It is typically co-administered with an inhibitor of peripheral decarboxylation (DDC, dopa decarboxylase), such as carbidopa or benserazide. Inhibitors of alternative metabolic route for dopamine by catechol-O-methyl transferase are also used. These include entacapone and tolcapone.
Peripheral effects[]
Dopamine also has effects when administered through an IV line outside the CNS. The brand name of this preparation is known as Intropin. The effects in this form are dose dependent.
Dosages from 2 to 5 μg/kg/min are considered the "renal dose."[citation needed] At this low dosage, dopamine binds D1 receptors, dilating blood vessels, increasing blood flow to renal, mesenteric, and coronary arteries; and increasing overall renal perfusion.[34] Dopamine therefore has a diuretic effect, potentially increasing urine output from 5 ml/kg/hr to 10 ml/kg/hr.[citation needed]
Intermediate dosages from 5 to 10 μg/kg/min additionally have a positive inotropic and chronotropic effect through increased β1 receptor activation. It is used in patients with shock or heart failure to increase cardiac output and blood pressure.[34] Dopamine begins to affect the heart at the lower doses, from about 3 mcg/kg/min IV.[citation needed]
High doses from 10 to 20 μg/kg/min is the "pressor" dose.[citation needed] This dose causes vasoconstriction, increases systemic vascular resistance, and increases blood pressure through α1 receptor activation;[34] but can cause the vessels in the kidneys to constrict to the point where they will become non-functional.[citation needed]
Dopamine and fruit browning[]
Polyphenol oxidases (PPOs) are a family of enzymes responsible for the browning of fresh fruits and vegetables when they are cut or bruised. These enzymes use molecular oxygen (O2) to oxidise various 1,2-diphenols to their corresponding quinones. The natural substrate for PPOs in bananas is dopamine. The product of their oxidation, dopamine quinone, spontaneously oxidises to other quinones. The quinones then polymerise and condense with amino acids and proteins to form brown pigments known as melanins. The quinones and melanins derived from dopamine may help protect damaged fruit and vegetables against growth of bacteria and fungi.[35]
References[]
- ↑ http://www.encyclopedia.com/doc/1O87-ventraltegmentalarea.html Reference for VTA.
- ↑ Benes, F.M. Carlsson and the discovery of dopamine. Trends in Pharmacological Sciences, Volume 22, Issue 1, 1 January 2001, Pages 46-47.
- ↑ Fahn, Stanley, "The History of Levodopa as it Pertains to Parkinson’s Disease," Movement Disorder Society’s 10th International Congress of Parkinson's Disease and Movement Disorders on November 1, 2006, in Kyoto, Japan.
- ↑
- ↑ Schultz, Cambridge university, UK
- ↑
- ↑
- ↑
- ↑
- ↑ 10.0 10.1 10.2 10.3 10.4 Cite error: Invalid
<ref>tag; name "fn5" defined multiple times with different content Cite error: Invalid<ref>tag; name "fn5" defined multiple times with different content Cite error: Invalid<ref>tag; name "fn5" defined multiple times with different content Cite error: Invalid<ref>tag; name "fn5" defined multiple times with different content - ↑
- ↑
- ↑
- ↑
- ↑
- ↑ Jensen TS, Yaksh TL.Effects of an intrathecal dopamine agonist, apomorphine, on thermal and chemical evoked noxious responses in rats.Brain Res. 1984 Apr 2;296(2):285-93
- ↑ Flores JA, El Banoua F, Galán-Rodríguez B, Fernandez-Espejo E.Opiate anti-nociception is attenuated following lesion of large dopamine neurons of the periaqueductal grey: critical role for D1 (not D2) dopamine receptors.Pain. 2004 Jul;110(1-2):205-14.
- ↑ Shyu BC, Kiritsy-Roy JA, Morrow TJ, Casey KL.Neurophysiological, pharmacological and behavioral evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia.Brain Res. 1992 Feb 14;572(1-2):216-23.
- ↑ Chudler EH, Dong WK.The role of the basal ganglia in nociception and pain.Pain. 1995 Jan;60(1):3-38
- ↑ Altier N, Stewart J.The role of dopamine in the nucleus accumbens in analgesia.Life Sci. 1999;65(22):2269-87
- ↑ Burkey AR, Carstens E, Jasmin L.Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception.J Neurosci. 1999 May 15;19(10):4169-79.
- ↑ Coffeen U, López-Avila A, Ortega-Legaspi JM, del Angel R, López-Muñoz FJ, Pellicer F.Dopamine receptors in the anterior insular cortex modulate long-term nociception in the rat.Eur J Pain. 2008 Jul;12(5):535-43.
- ↑ López-Avila A, Coffeen U, Ortega-Legaspi JM, del Angel R, Pellicer F.Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulate cortex.Pain. 2004 Sep;111(1-2):136-43.
- ↑ Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O.Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.Mov Disord. 2005 Dec;20(12):1557-63.
- ↑ Jääskeläinen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, Bergman J.Role of the dopaminergic system in chronic pain -- a fluorodopa-PET study.Pain. 2001 Feb 15;90(3):257-60.
- ↑ Wood PB, Patterson JC 2nd, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL.Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study.J Pain. 2007 Jan;8(1):51-8.
- ↑ Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell MC, Chizh BA.Fibromyalgia patients show an abnormal dopamine response to pain.Eur J Neurosci. 2007 Jun;25(12):3576-82.
- ↑ Cervenka S, Pålhagen SE, Comley RA, Panagiotidis G, Cselényi Z, Matthews JC, Lai RY, Halldin C, Farde L.Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.Brain. 2006 Aug;129(Pt 8):2017-28.
- ↑ Wood PB.Role of central dopamine in pain and analgesia.Expert Rev Neurother. 2008 May;8(5):781-97.
- ↑
- ↑
- ↑ Disruption of gene interaction linked to schizophrenia. St. Jude Children's Research Hospital. Retrieved on 2006-07-06.
- ↑
- ↑ 34.0 34.1 34.2 Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview, 8. ISBN 1-59541-101-1.
- ↑
See also[]
- Addiction
- Amphetamine
- Antipsychotic
- Catecholamine
- Catechol-O-methyl transferase
- Classical conditioning
- Operant conditioning
- Cocaine
- Depression
- Dopamine hypothesis of schizophrenia
- Dopamine reuptake inhibitors
- Methylphenidate
- Neurotransmitter
- Parkinson's disease
- Prolactinoma
- Schizophrenia
- Selegiline
- Serotonin
External links[]
- DrugBank APRD00085
| {{{header}}} |
|---|
| {{{body}}} |
| {{{header}}} |
|---|
| {{{body}}} |
bg:Допамин ca:Dopamina cs:Dopamin da:Dopamin de:Dopamin dv:ޑޯޕަމީން et:Dopamiin es:Dopamina fr:Dopamine ko:도파민 hr:Dopamin it:Dopamina he:דופמין lt:Dopaminas hu:Dopamin nl:Dopamine ja:ドーパミン no:Dopamin pl:Dopamina pt:Dopamina ru:Дофамин sl:Dopamin sr:Допамин fi:Dopamiini sv:Dopamin th:โดพามีน tr:Dopamin uk:Дофамін zh:多巴胺